Spinoff Redvax sold to Pfizer

Redbiotec has successfully developed a CMV vaccine program based on its rePAX® technology. This program was sold to Pfizer. See Pfizer press release, January 5 2014. Pfizer press release.

“Through the acquisition of the Redvax innovative CMV vaccine platform and expertise we will seek to develop a vaccine to prevent a difficult disease that can have a devastating and lifelong impact on young children,” said Kathrin U. Jansen, a senior vice president of Pfizer.

See also investor statement Redalpine blog.


Herpes and Influenza vaccines (update Feb 2016)

Redbiotec has generated a library of novel antigens for herpes simplex virus (HSV-2). The antigens are currently being tested with human blood samples for their potential as vaccine candidates.

Redbiotec is the commercial leader of an EU-funded program with the goal to develop a broadly protective Influenza vaccine.

Beyond its vaccine activities Redbiotec is exploring the broadening of its technology platform (materials science, microorganisms engineering)


Further HSV-2 vaccine expert joins Redbiotec 
Schlieren, 26 September 2016
Redbiotec announces today the appointment of Research Associate Professor Sita Awasthi from the University of Pennsylvania,Infectious Disease Division, Perelman School of Medicine, to its team. Sita Awasthi is a leading expert in vaccine development and immunology of infectious diseases, and will support Redbiotec in its Herpes Simplex Virus vaccine program.
Three new patents for Redbiotec's Herpes simplex vaccine program
Schlieren, 17 March 2016
Redbiotec has filed a new patent application covering its novel antigens against Herpes simplex viruses. The antigens developed by Redbiotec comprise potent trimers and dimers as well as combinations thereof. Redbiotec expects first results from its ongoing in vitro and in vivo studies by Q2 2016.
Further news